SCHEMBL6310079

SCHEMBL6310079

O=C(c1ccc(Cl)cc1)c1ccc2nc(Cl)cc(-c3cccc(Cl)c3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.42
MAP4K4 O95819 1/20 0.41
LTB4R Q15722 2/20 0.41
MAPK1 P28482 1/20 0.40
SRD5A2 P31213 2/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
HPGD P15428 1/20 0.40
CDH1 P12830 1/20 0.39
APC P25054 1/20 0.39
CTNNB1 P35222 1/20 0.39
TCF7L2 Q9NQB0 1/20 0.39
CNR2 P34972 1/20 0.39
GRM5 P41594 1/20 0.39
CHEK2 O96017 1/20 0.39
FABP3 P05413 1/20 0.38
FABP4 P15090 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5656211 0.99 CNR1 (0.41) CNR1MAP4K4LTB4RMAPK1SRD5A2
SCHEMBL5782390 0.89 CNR2 (0.52) CNR1MAPK1CNR2GRM5FABP3
SCHEMBL5782504 0.88 GRM5 (0.45) MAP4K4LTB4RCNR2GRM5FABP3
SCHEMBL5027012 0.86 LTB4R (0.37) MAP4K4LTB4RCSNK2A2CSNK2B
SCHEMBL5656596 0.85 LTB4R (0.46) CNR1MAP4K4LTB4RHPGDGRM5
SCHEMBL5654539 0.83 LTB4R (0.40) MAP4K4LTB4RFABP3FABP4LMNA
SCHEMBL14039064 0.80 CSNK2A2 (0.47) SRD5A2CSNK2A2CSNK2BCDH1APC
SCHEMBL5782688 0.78 CSNK2A2 (0.46) MAPK1CSNK2A2CSNK2BCDH1APC
SCHEMBL5655139 0.78 LTB4R (0.44) MAP4K4LTB4RCSNK2A2CSNK2BCNR2
SCHEMBL12590511 0.78 FNTA (0.38) LTB4RCSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6914066-B2 1,2-annelated quinoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-07-05 US disclosed
CN-1178938-C 1,2-annelated quinoline derivatives ղɭҩҵ���޹�˾ 2004-12-08 CN disclosed
US-20030119843-A1 1,2-annelated quinoline derivatives JANSSEN PHARMACEUTICA, N.V. 2003-06-26 US disclosed
EP-1140935-B1 1,2-ANNELATED QUINOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2003-05-14 EP disclosed
US-6458800-B1 1,2-annelated quinoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2002-10-01 US disclosed
CN-1331693-A 1,2-annelated quinoline derivatives JANSSEN PHARMACEUTICA NV (BE) 2002-01-16 CN disclosed
EP-1140935-A2 1,2-ANNELATED QUINOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2001-10-10 EP disclosed
WO-2000039082-A2 1,2-ANNELATED QUINOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119843-A1 1,2-annelated quinoline derivatives NAT1, CYP7A1, CYP4A11 CNR1 396/4885MAP4K4 4624/4885LTB4R 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.